Mint Medical, a Snke company, and mediaire announce a collaboration to advance AI‑powered MRI workflows through the interoperability of mint Lesion and mdprostate.
The collaboration connects structured reporting with AI‑driven quantitative image analysis, enabling more integrated and efficient patient management.
Prostate cancer is the most common cancer in men in Europe, with more than 330,000 new cases and approximately 76,000 deaths reported each year (1), underscoring the need for precise diagnostics and consistent follow‑up care.
The integration of the software solutions from mediaire and Mint Medical enables radiologists to access AI-generated insights from mdprostate seamlessly with mint Lesion supporting structured reporting, improving diagnostic consistency, and enabling longitudinal tracking of findings over time.
Onur Özek, Managing Director at Mint Medical, emphasizes:
“The interoperability with mdprostate represents an important milestone in delivering AI‑enhanced value to customers. Embedding additional AI capabilities directly into mint Lesion strengthens workflow efficiency and supports the consistent use of advanced imaging analytics in routine follow‑ups.”
The integration of mdprostate and mint Lesion provides a streamlined workflow for the characterization and documentation of prostate MRI. Published clinical evidence in the European Journal of Radiology (2) demonstrates mdprostate's performance in identifying and grading lesions using PI-RADS criteria. While mediaire's solution offers automated detection across biparametric and multiparametric MRI, mint Lesion provides the structured interface for the guided assessment of the peripheral and transition zones.
This collaborative solution automatically determines PSA density, lesion volumes and incorporates PI-QUAL v2. It ensures interoperability with biopsy fusion systems to assist in subsequent procedures. By combining these automated analytics with standardized reporting, the two systems support the clinical pathway from initial imaging to targeted biopsy.
Andreas Lemke, CEO of mediaire, states:
“This partnership perfectly aligns with our ambition to be a dedicated MRI specialist addressing the workflow end‑to‑end. Our solutions are highly complementary, and together we enhance our customers’ workflows while expanding our mutual geographical reach and growth opportunities.”
Together, Mint Medical and mediaire provide radiology departments with a scalable, interoperable ecosystem that combines structured reporting excellence with advanced AI‑powered MRI insights. This partnership is particularly critical for following prostate cancer patients, as mediaire delivers detailed AI‑driven imaging insights while mint Lesion provides the tools to adjust care plans, track findings over time, and ensure consistent patient follow‑up. By combining these strengths, the integrated solution supports greater efficiency, consistency, and clinical confidence throughout the patient journey.
About Mint Medical
Mint Medical, a Snke company, is a global leader in software solutions for structured reporting and data-driven radiology. Its flagship platform, mint Lesion, streamlines the diagnostic workflow in clinical routine and research by transforming medical images into high-quality, reproducible data.
Mint Medical provides a vendor-neutral ecosystem that integrates advanced, AI-augmented solutions from third-party partners - including automated lesion detection and segmentation - directly into the radiologist’s reading process. By bridging the gap between imaging findings and standardized clinical criteria, Mint Medical enables the precise, longitudinal assessments essential for the advancement of precision medicine.
Contact
Corina Leibli, VP MarCom corina.leibli@mint-medical.com, +49 6221 32180-21
Dr. Sigrid Auweter, Product Management, sigrid.auweter@mint-medical.com
More information: www.mint-medical.com
About mediaire
mediaire provides deep learning–based AI solutions embedded along the entire MRI workflow to support faster and more confident diagnostic decisions while reducing the risk of missed critical findings.
With a clear MRI-first focus, mediaire delivers clinically validated solutions across brain, prostate and knee imaging. Supported by more than 40 published scientific studies and trusted by hospitals, outpatient centers and radiology networks, mediaire combines deep MRI expertise with real-world workflow integration to bring reliable AI into everyday clinical practice.
mdprostate is one of the leading AI solutions for prostate carcinoma detection and characterization on MRI, with clinical evidence published in the European Journal of Radiology (2) demonstrating performance metrics comparable to expert radiologists in identifying and grading lesions using PI‑RADS criteria.
The product is one of the most comprehensive in the market, compatible with biparametric and multiparametric MRI, automatically delivering all prostate and lesion measurements, generating schematics, and enabling export to biopsy fusion systems.
Contact
Cécile Hourquet, Scientific Marketing Lead
c.hourquet@mediaire.de
More information: mediaire.ai/
Sources:
1 European Cancer Organization, Bericht 2025
2 Bayerl et al., European Journal of Radiology, 2025
